• Publications
  • Influence
An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.
TLDR
This document represents the current state of knowledge regarding idiopathic pulmonary fibrosis, and contains sections on definition and epidemiology, risk factors, diagnosis, natural history, staging and prognosis, treatment, and monitoring disease course. Expand
An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.
TLDR
This update is a supplement to the previous 2002 IIP classification document and outlines advances in the past decade and potential areas for future investigation. Expand
Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline
TLDR
The guideline panel provided recommendations related to the diagnosis of IPF, including a conditional recommendation for multidisciplinary discussion and a strong recommendation against measurement of serum biomarkers for the sole purpose of distinguishing IPF from other ILDs. Expand
An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline.
TLDR
This document updates the American Thoracic Society/European Respiratory Society/Japanese Respiratories Society/Latin American ThorACic Association guideline on idiopathic pulmonary fibrosis treatment with new recommendations made for or against specific treatment interventions. Expand
Incidence and prevalence of idiopathic pulmonary fibrosis.
TLDR
The results suggest that idiopathic pulmonary fibrosis is probably more common in the United States than previously reported. Expand
Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis.
TLDR
In patients with idiopathic pulmonary fibrosis, BIBF 1120 at a dose of 150 mg twice daily, as compared with placebo, was associated with a trend toward a reduction in the decline in lung function, with fewer acute exacerbations and preserved quality of life. Expand
A new classification system for chronic lung allograft dysfunction.
TLDR
The term chronic lung allograft dysfunction (CLAD) has been introduced to cover all forms of graft dysfunction, but the definition and flow chart are proposed that may facilitate recognition of the different phenotypes of CLAD that can complicate the clinical course of lung transplant recipients. Expand
Pirfenidone in idiopathic pulmonary fibrosis
TLDR
Although photosensitivity, a well-established side-effect of pirfenidone, was the major adverse event in this study, it was mild in severity in most of the patients and relatively well tolerated in patients with IPF. Expand
An official American Thoracic Society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease.
TLDR
Recommendations for the performance and processing of BAL, as well as the interpretation of BAL findings, were formulated by the committee and frequently provide useful information for the diagnostic evaluation of patients with suspected ILD. Expand
Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report.
TLDR
To better reflect the current state of knowledge and improve the feasibility of future research into its etiology and treatment, the working group proposes a new conceptual framework for acute respiratory deterioration in idiopathic pulmonary fibrosis and a revised definition and diagnostic criteria for acute exacerbation. Expand
...
1
2
3
4
5
...